Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (341-350 of 520) with videos related to

Pageof 52
Sort By:
European Journal of Heart Failure|June 1, 2005
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeEileen O'Meara, Eldrin Lewis, Chris Granger, et al.
Circulation. Heart Failure|January 22, 2015
Exercise training as therapy for heart failure: current status and future directionsJerome L Fleg, Lawton S Cooper, Barry A Borlaug, et al.
The American Journal of Cardiology|January 8, 2019
Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study)Thao Huynh, Brian J Harty, Brian Claggett, et al.
Circulation|February 8, 2006
Renal function as a predictor of outcome in a broad spectrum of patients with heart failureHans L Hillege, Dorothea Nitsch, Marc A Pfeffer, et al.
American Heart Journal|July 15, 2006
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programAnique Ducharme, Karl Swedberg, Marc A Pfeffer, et al.
European Journal of Heart Failure|October 28, 2022
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
European Journal of Heart Failure|January 19, 2013
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)John J V McMurray, Inder S Anand, Rafael Diaz, et al.
Cardiovascular Diabetology|June 18, 2022
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trialsMagnus O Wijkman, Brian Claggett, Muthiah Vaduganathan, et al.
Circulation. Heart Failure|March 16, 2019
N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation StatusSøren L Kristensen, Ulrik M Mogensen, Pardeep S Jhund, et al.
The New England Journal of Medicine|November 6, 2012
Cardiorenal end points in a trial of aliskiren for type 2 diabetesHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.
Pageof 52

Showing results (341-350 of 520) with videos related to

Sort By:
Pageof 52
European Journal of Heart Failure|June 1, 2005
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeEileen O'Meara, Eldrin Lewis, Chris Granger, et al.
Circulation. Heart Failure|January 22, 2015
Exercise training as therapy for heart failure: current status and future directionsJerome L Fleg, Lawton S Cooper, Barry A Borlaug, et al.
The American Journal of Cardiology|January 8, 2019
Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study)Thao Huynh, Brian J Harty, Brian Claggett, et al.
Circulation|February 8, 2006
Renal function as a predictor of outcome in a broad spectrum of patients with heart failureHans L Hillege, Dorothea Nitsch, Marc A Pfeffer, et al.
American Heart Journal|July 15, 2006
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programAnique Ducharme, Karl Swedberg, Marc A Pfeffer, et al.
European Journal of Heart Failure|October 28, 2022
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
European Journal of Heart Failure|January 19, 2013
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)John J V McMurray, Inder S Anand, Rafael Diaz, et al.
Cardiovascular Diabetology|June 18, 2022
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trialsMagnus O Wijkman, Brian Claggett, Muthiah Vaduganathan, et al.
Circulation. Heart Failure|March 16, 2019
N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation StatusSøren L Kristensen, Ulrik M Mogensen, Pardeep S Jhund, et al.
The New England Journal of Medicine|November 6, 2012
Cardiorenal end points in a trial of aliskiren for type 2 diabetesHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.
Pageof 52